Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 3/20 | 0.45 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.45 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.45 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.45 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.45 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.45 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.45 |
| ▸ | APLNR | P35414 | 2/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4074652 | 0.98 | GABRA5 (0.44) | GABRA5SLC6A1GABRB2SLC6A12SLC6A11 | |
| SCHEMBL20744613 | 0.88 | APLNR (0.52) | GABRA5SLC6A1GABRB2SLC6A12SLC6A11 | |
| SCHEMBL231062 | 0.86 | GABRA5 (0.39) | GABRA5SLC6A1GABRB2SLC6A12SLC6A11 | |
| Hydrochloric Acid SCHEMBL20744108 | 0.84 | GABRA5 (0.38) | GABRA5SLC6A1GABRB2SLC6A12SLC6A11 | |
| SCHEMBL25040330 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL31404636 | 0.79 | APLNR (0.31) | APLNR | |
| SCHEMBL1702703 | 0.79 | GABRA5 (0.42) | GABRA5SLC6A1GABRB2SLC6A12SLC6A11 | |
| SCHEMBL30804012 | 0.79 | APLNR (0.42) | GABRA5SLC6A1GABRB2SLC6A12SLC6A11 | |
| SCHEMBL6962134 | 0.78 | GABRA5 (0.50) | GABRA5SLC6A1GABRB2SLC6A12SLC6A11 | |
| SCHEMBL1081079 | 0.78 | GABRA5 (0.45) | GABRA5SLC6A1GABRB2SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1934 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106970-A1 | DIAGNOSIS AND TREATMENT OF DISEASES COMPLICATED BY SOLUBLE TARGET IN BLOOD | CURADEL SURGICAL INNOVATIONS, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260133198-A1 | DIAGNOSIS AND TREATMENT OF DISEASES COMPLICATED BY SOLUBLE TARGET IN BLOOD | CURADEL SURGICAL INNOVATIONS, INC. (US) | 2026-05-14 | — | — | US | claimed |
| CN-122011203-A | Chimeric antigen receptor with chimeric intracellular signaling domain based on cd3ζ and cd3δ and uses thereof | 天宜康医药(上海)有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4732851-A1 | LINKER, ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR | Fudan University (CN) | 2026-04-29 | — | — | EP | claimed |
| US-20260102335-A1 | IMMUNE CELLS EXPRESSING ENGINEERED ANTIGEN RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-04-16 | — | — | US | claimed |
| EP-4724500-A2 | MULTISPECIFIC MOLECULES BINDING TO TCR AND USES THEREOF | Marengo Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-3967329-B1 | ENGINEERED IMMUNE CELL TARGETING BCMA AND USE THEREOF | GRACELL BIOSCIENCE SHANGHAI CO LTD (CN) | 2026-04-01 | — | — | EP | claimed |
| US-20260069217-A1 | APPARATUS AND SYSTEMS FOR EVENT DETECTION USING PROBABILISTIC MEASURES | FLINT HILLS SCIENTIFIC, L.L.C. (US) | 2026-03-12 | — | — | US | claimed |
| EP-4704897-A1 | COMBINATION THERAPIES USING MOLECULES BINDING TO TCR | Marengo Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4706675-A1 | CYSTEINE-ENGINEERED CHIMERIC ANTIGEN RECEPTOR | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-03-11 | — | — | EP | claimed |
| CN-114284518-A | Application of PMSA composite membrane obtained based on interface super-assembly in salt gradient energy conversion | 复旦大学 | 2022-04-05 | — | — | CN | claimed |
| EP-3969483-A1 | ULTRASPECIFIC CELL TARGETING USING DE NOVO DESIGNED CO-LOCALIZATION DEPENDENT PROTEIN SWITCHES | University of Washington (US) | 2022-03-23 | — | — | EP | claimed |
| EP-3969482-A1 | LOCKR-MEDIATED RECRUITMENT OF CAR T CELLS | University of Washington (US) | 2022-03-23 | — | — | EP | claimed |
| WO-2022052913-A1 | COMPOSITIONS AND METHODS FOR T CELL ENGINEERING | GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. (CN) | 2022-03-17 | — | — | WO | claimed |
| EP-3967329-A1 | ENGINEERED IMMUNE CELL TARGETING BCMA AND USE THEREOF | Gracell Biotechnologies (Shanghai) Co., Ltd. (CN) | 2022-03-16 | — | — | EP | claimed |
| CN-114181960-A | Chimeric antigen receptors and methods of use | 美天施生物科技有限公司 | 2022-03-15 | — | — | CN | claimed |
| EP-3964238-A1 | BCMA-TARGETING ENGINEERED IMMUNE CELL AND USE THEREOF | Gracell Biotechnologies (Shanghai) Co., Ltd. (CN) | 2022-03-09 | — | — | EP | claimed |
| CN-114139935-A | Method based on OMS and PMS basic data sharing function | 国网山东省电力公司日照供电公司 | 2022-03-04 | — | — | CN | claimed |
| US-20220049004-A1 | ENGINEERED IMMUNE CELLS TARGETING BCMA AND THEIR USES THEREOF | GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. (CN) | 2022-02-17 | — | — | US | claimed |
| CN-114040779-A | Conjugates of cell binding molecules containing branched linkers and cytotoxic agents | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260133198-A1 | DIAGNOSIS AND TREATMENT OF DISEASES COMPLICATED BY SOLUBLE TARGET IN BLOOD | KLK3, FUCA2, FAP | GABRA5 3435/4885SLC6A1 3495/4885GABRB2 3480/4885 |
| US-20260069217-A1 | APPARATUS AND SYSTEMS FOR EVENT DETECTION USING PROBABILISTIC MEASURES | STS, NLN, PYGB | GABRA5 777/4885SLC6A1 2304/4885GABRB2 1340/4885 |
| US-20260102335-A1 | IMMUNE CELLS EXPRESSING ENGINEERED ANTIGEN RECEPTORS | CD74, TP53, CAMK2D | GABRA5 3561/4885SLC6A1 4764/4885GABRB2 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.